IN THE SPECIFICATION

The paragraph beginning at line 1, page 18 has been amended as follows:

$a^1$ 2-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylic acid

The paragraph beginning at line 17, page 18 has been amended as follows:

$a^2$ 1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylic acid

The paragraph beginning at line 19, page 18 has been amended as follows:

$a^3$ 1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylic acid

The paragraph beginning at line 9 of page 19 has been amended as follows:

$a^4$ methyl 3-({1-[(5-{[(4-chlorobenzoyl)amino]-methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate

The paragraph beginning at line 5 of page 24 has been amended as follows:

$a^5$ methyl 3-{[1-({5-[({3-nitrobenzoyl}amino)methyl]-thien-2-yl}sulfonyl)-piperidin-4-yl]amino}benzoate

The paragraph beginning at line 9 of page 25 has been amended as follows: ✓

a6

methyl 3-{[1-({5-[({4-nitrobenzoyl}amino)methyl]-thien-2-yl}sulfonyl)piperidin-4-yl]amino}benzoate

The paragraph beginning at line 11 of page 29 has been amended as follows: ✓

a7

methyl 3-({1-[(5-{[(3-methoxybenzoyl)amino]-methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate

The paragraph beginning at line 3 of page 37 has been amended as follows: ✓

a8

- Two further compounds are rather incidentally disclosed in WO 97/45403 (i.e. 2-{[2-(benzoylaminomethyl)-thiophene]-5-sulfonyl}-1,2,3,5,6,7-hexahydro-N,N-~~dipropylcyanopent[f]isoindol-~~dipropylcyclopent[f]isoindol-6-amine as selective dopamine D3 ligand) and in WO 97/30992 (i.e. N-[[5-[[7-cyano-1,2,3,5-tetrahydro-1-(1H-imidazol-4-yl-methyl)-3-(phenylmethyl)-4H-1,4-benzodiazepin-4-yl]sulfonyl]-2-thienyl] methyl] benzamide and its hydrochloride to be used for inhibiting farnesyl-protein transferase).

The paragraph beginning at line 1 of page 54 has been amended as follows: ✓

a9

~~91a~~ Fraction 1 (250 mg, 0.82 mmol) was dissolved in 5 mL $CH_2Cl_2$. 1_mL of TFA was added dropwise and the solution was stirred for 3h. The solvents were evaporated to dryness and the oily residue was precipitated with diethylether to give 240 mg (95%) of ~~XX1~~**91a**: $^1$H NMR (DMSO-*d6*) δ 9.10 (b, m, 1H), 8.72 (b, m, 1H), 8.07 (d, *J* = 8.3 Hz., 1H), 7.96 (d, *J* = 8.3 Hz, 1H), 7.55 (t, *J* = 8.3 Hz.), 7.40 (t, *J* = 8.3 Hz.), 5.25 (m, 1H), 3.52 (m, 2H), 3.20 (m, 2H), 2.55-2.25 (m, 4H), M/Z APCI: 203.2 (M+1).

The paragraph beginning at line 18 of page 54 has been amended as follows: ✓

a10

Alternatively ~~3~~ **91** can be synthesised in a parallel solution phase approach using the protocol applied for **2**.

The paragraph beginning at line 1 of page 74 has been amended as follows: ✓

a11

5-Diallylaminomethyl-thiophene-2-sulfonyl chloride ~~229b~~ **269b** (270 mg, 1.88_mmol) and DIEA (0.88_mL, 5.13_mmol) were dissolved in 10 mL chloroform. This solution was added methylisonipecotate (269 mg, 1.88_mmol) in 1 mL chloroform. The reaction was stirred for 3h, diluted with $CH_2Cl_2$ and extracted with HCl (0.1N), $NaHCO_3$ sat. and brine. The organic

contd.
a11

layer was dried over $MgSO_4$ and evaporated to dryness. The crude was purified by flash chromatography on silica gel using cyclohexane/EtOAc 1:1 as eluent to obtain 440 mg (65%) of **327a** as colorless oil: $H^1$ NMR ($CDCl_3$) δ 7.30 (d, $J$ = 3.6 Hz, 1H), 6.83 (d, $J$ = 3.6 1H), 5.78 (m, 2H), 5.18 (m, 4H), 3.70 (s, 2H), 3.52 (m, 6H), 3.07 (m, 4H), 2.50 (m, 2H), 2.25 (m, 1H), 1.93 (m, 2H), 1.84 (m, 2H). M/Z APCI: 399.2 (M+1)

The paragraph beginning at line 12 of page 76 has been amended as follows: ✓

a12

A solution of 4-chlorobenzoyl chloride (3.2 g, 18.5 ~~mol~~mmol) in 50 ml dry $CH_2Cl_2$ was added over 30 min to a stirred solution of 2-furfurylamine (2g, 20.6 ~~mol~~mmol) and $^iPr_2NEt$ (7 ml, 41 ~~mol~~mmol) in $CH_2Cl_2$ (200 ml) at 0°C. The reaction was allowed to warm to room temperature over 3 h. The mixture was diluted with 200 ml of $CH_2Cl_2$, washed twice with HCl aq. (1N) and dried over $MgSO_4$. Evaporation of the solvent afforded 4g (83%) of the title benzamide as a white solid: $^1H$ NMR (DMSO-$d^6$) δ 9.05 (t, $J$ = 5.7 Hz, 1H), 7.89 (d, $J$ = 8.7 Hz, 2H), 7.57 (m, 1H), 7.53 (d, $J$ = 8.7 Hz, 2H), 6.40 (dd, $J$ = 3.7, 1.1 Hz, 1H), 6.28 (d, $J$ = 3.7 Hz, 1H), 4.46 (d, $J$ = 5.6 Hz, 2H). M/Z APCI−: 236.6 (M+1), 234.8 (M-1).

The paragraph beginning at line 5 of page 79 has been amended as follows: ✓

a 13

At -80°C oxalylchloride (36_mg, 0.28_mmol) was dissolved in dry $CH_2Cl_2$, while DMSO (50_ul, 0.6 mmol) were added slowly. The solution was stirred under Ar. For 15'. **351a** (100_mg, 0.25_mmol) was dissolved in 2_ml $CH_2Cl_2$, and this solution was added dropwise to the above reaction mixture at -80°C. The reaction was stirred for 15' at low temperature, before DIEA (0.21_ml, 1.25_mmol) was added. The reaction was stirred at -80°C for 30' and allowed to warm to rt. during 2h. A white solid was formed, the reaction was quenched with water and extracted with $CH_2Cl_2$ several times. The combined organic layers were dried over $MgSO_4$ and evaporated to dryness. The crude was purified by flash chromatography on silica gel using EtOAc/cyclohexane 2:1 as eluent. **351b** (80_mg, 80%) was obtained as a colourless solid.: $H^1$ NMR ($CDCl_3$) δ 7.72 (d, $J$ = 8.7 Hz, 2H), 7.46 (d, $-J$ = 3.8 Hz, 1H), 7.42 (d, $J$ = 8.7 Hz, 2H), 7.08 (d, $-J$ = 3.8 Hz, 1H), 6.59 (t, $J$ = 5.8 Hz, 1H), 4.80 (d, $J$ = 6.0 Hz, 2H), 3.58 (t, $J$ = 7.5 Hz, 2H), 3.50 (s, 3H), 2.54 (t, $J$ = 7.5, 2H), 3.35-3.23 (m, 3H), 2.95 (m, 2H), 1.94 (m, 2H), 1.86 (m, 2H), 1.70-1.50 (m, 5H), 1.30-1.20 (m, 8H), 0.87 (t, $J$ = 6.8, 3H), M/Z APCI 399.0 (M+1), 397.2 (M-1)